Emerging drugs for the treatment of cocaine use disorder: A review of neurobiological targets and pharmacotherapy

Expert Opinion on Emerging Drugs

Volumn 20, Issue 1, 2015, Pages 15-29

  Shorter, Daryl ^a   Domingo, Coreen B ^a   Kosten, Thomas R ^b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical trial; Cocaine; Pharmacogenetics; Phase II; Phase III

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; CARBIDOPA PLUS LEVODOPA; COCAINE; COCAINE VACCINE; DEXAMPHETAMINE; DISULFIRAM; DOPAMINE RECEPTOR STIMULATING AGENT; DOXAZOSIN; MODAFINIL; NEPICASTAT; NEUROTRANSMITTER; TOPIRAMATE; UNCLASSIFIED DRUG; VACCINE; VIGABATRIN;

AGITATION; COCAINE DEPENDENCE; DATA BASE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DSM-5; FATIGUE; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HUMAN; HYPERSOMNIA; INCREASED APPETITE; INSOMNIA; MESOCORTICOLIMBIC DOPAMINE SYSTEM; NEUROBIOLOGY; NORADRENERGIC SYSTEM; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PSYCHOMOTOR RETARDATION; PUBLIC HEALTH PROBLEM; REVIEW; REWARD; TREATMENT DURATION; TREATMENT RESPONSE; UNPLEASANT DREAM; ANIMAL; CLINICAL TRIAL (TOPIC); COCAINE-RELATED DISORDERS; DRUG DESIGN; HEALTH; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; CLINICAL TRIALS AS TOPIC; COCAINE-RELATED DISORDERS; DRUG DESIGN; GLOBAL HEALTH; HUMANS; MOLECULAR TARGETED THERAPY; PHARMACOGENETICS; RESEARCH DESIGN;

EID: 84923268157     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2015.985203     Document Type: Review

References (139)

1. CDC. National surveillance of cocaine use and related health consequences. MMWR Weekly 1982.31: 265-8, 273 Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/00001101.htm
2. Available from: http://www.unodc.org/documents/data-and-analysis/WDR2012/WDR-2012-web-small.pdf United Nations, NY 2012
3. Degenhardt L, Baxter AJ, Lee YY, et al. Global epidemiology and burden of disease of psychostimulant dependence: findings from global burden of disease study 2010. Drug Alcohol Depend 2014; 137: 36-47
4. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795 Substance Abuse and Mental Health Services Administration; Rockville, MD: 2013
5. Ettner SL, Huang D, Evans E, et al. Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"? Health Serv Res 2006; 41: 192-213
6. Hiller ML, Knight K, Simpson DD. Recidivism following mandated residential substance abuse treatment for felony probationers. Prison J 2006; 86: 230-41
7. McCollister KE, French MT, Inciardi JA, et al. Post-release substance abuse treatment for criminal offenders: a cost-effectiveness analysis. J Quant Criminol 2003; 19: 389-407
8. Laudet AB. Rates and predictors of employment among formerly polysubstance dependent urban individuals in recovery. J Addict Dis 2012; 31: 288-302
9. Naderi-Heiden A, Gleiss A, Backer C, et al. Mortality and employment after inpatient opiate detoxification. Eur Psychiatry 2012; 27: 294-300
10. Flynn PM, Kristiansen PL, Porto JV, Hubbard RL. Costs and benefits of treatment for cocaine addiction in DATOS. Drug Alcohol Depend 1999; 57: 167-74
11. Hubbard RL, Craddock SG, Anderson J. Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J Subst Abuse Treat 2003; 25: 125-34
12. Olmstead TA, Petry NM. The costeffectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs. Drug Alcohol Depend 2009; 102: 108-15
13. Prah Ruger J, Abdallah AB, Luekens C, Cottler L. Cost-effectiveness of peerdelivered interventions for cocaine and alcohol abuse among women: a randomized controlled trial. PLoS One 2012; 7 (3): e33594
14. Cartwright WS. Cocaine medications, cocaine consumption, and societal costs. Pharmacoeconomics 2000; 18: 405-13
15. Jofre-Bonet M, Sindelar JL, Petrakis IL, et al. Cost effectiveness of disulfiram: treating cocaine use in methadonemaintained patients. J Subst Abuse Treat 2004; 26: 225-32
16. Shearer J, Shanahan M, Darke S, et al. A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence. Drug Alcohol Rev 2010; 29: 235-42
17. Johanson CD, Fischman MW. The pharmacology of cocaine related to its abuse. Pharmacol Rev 1989; 41: 3-52
18. Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 2003; 479: 23-40
19. Parsons LH, Justice JB. Serotonin and dopamine sensitization in the nucleus accumbens, ventral tegmental area and dorsal raphe nucleus following repeated cocaine administration. J Neurochem 1993; 61: 1611-19
20. Pentkowski NS, Acosta JI, Browning JR, et al. Stimulation of 5-HT (1B) receptors enhances cocaine reinforcement yet reduces cocaine-seeking behavior. Addict Biol 2009; 14: 419-30
21. French MT, McGeary KA, Chitwood DD, et al. Chronic illicit drug use, health services utilization and the cost of medical care. Soc Sci Med 2000; 50: 1703-13
22. Chaisson RE, Bacchetti P, Osmond D, et al. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA 1989; 261: 561-5
23. Chaisson MA, Stoneburner RL, Hildebrandt DS, et al. Heterosexual transmission of HIV-1 associated with the use of smokeable freebase cocaine (crack). AIDS 1991; 5: 1121-6
24. Estrada AL. Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users. Public Health Rep 2002; 117: S126-34
25. Carvalho HB, Seibel SD. Crack cocaine use and its relationship with violence and HIV.Clinics (Sao Paulo). 2009; 64: 857-66
26. Falck RS, Wang J, Carlson RG, et al. The prevalence and correlates of depressive symptomatology among a community sample of crack-cocaine smokers. J Psychoactive Drugs 2002; 34: 281-8
27. Najavits LM, Runkel R, Neuner C, et al. Rates and symptoms of PTSD among cocaine-dependent patients. J Stud Alcohol 2003; 64: 601-6
28. Gudjonsson GH, Sigurdsson JF, Sigfusdottir ID, et al. An epidemiological study among young persons and the relationship with cigarette smoking, alcohol consumption, and illicit drug use. J Child Psychol Psychiatry 2012; 53: 304-12
29. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 13-4760, DAWN Series D-39 Substance Abuse and Mental Health Services Administration; Rockville, MD: 2013
30. Volkow ND, Wang GJ, Fischman MW, et al. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci 2000; 67: 1507-15
31. Resnick RB, Kestenbaum RS, Schwartz LK. Acute systemic effects of cocaine in man: a controlled study by intranasal and intravenous routes. Science 1977; 195: 696-8
32. Perez-Reyes M, Di Guiseppi S, Ondrusek G, et al. Free-base cocaine smoking. Clin Pharmacol Ther 1982; 32: 459-65
33. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003; 160: 1909-18
34. Sofuoglu M, Brown S, Dudish-Poulsen S, et al. Individual differences in the subjective response to smoked cocaine in humans. Am J Drug Alcohol Abuse 2000; 26: 591-602
35. Kosten TR. Pathophysiology and treatment of cocaine dependence. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: the fifth generation of progress. Lippincott Williams & Wilkins; Baltimore, MD: 2002. p. 1461-73
36. Menaker J, Farcy DA, Boswell SH, et al. Cocaine-induced agitated delirium with associated hyperthermia: a case report. J Emerg Med 2011; 41: e49-53
37. Wetli CV, Mash D, Karch SB. Cocaine-associated agitated delirium and the neuroleptic malignant syndrome. Am J Emerg Med 1996; 14: 425-8
38. Brady KT, Lydiard RB, Malcolm R, et al. Cocaine-induced psychosis. J Clin Psychiatry 1991; 52: 509-12
39. Hayes BD, Martinez JP, Barrueto F Jr. Drug-induced hyperthermic syndromes: part I. Hyperthermia in overdose. Emerg Med Clin North Am 2013; 31: 1019-33
40. Hoffman RS. Treatment of patients with cocaine-induced arrhythmias: bringing the bench to the bedside. Br J Clin Pharmacol 2010; 69: 448-57
41. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. American Psychiatric Association, Washington, DC: 2013
42. Gawin FH, Ellinwood EH. Cocaine and other stimulants: actions, abuse, and treatment. N Engl J Med 1988; 318: 1173-82
43. Walsh SL, Stoops WW, Moody DE, et al. Repeated dosing with oral cocaine in humans: assessment of direct effects, withdrawal and pharmacokinetics. Exp Clin Psychopharmacol 2009; 17: 205-16
44. Ahmadi J, Kampman K, Dackis C, et al. Cocaine withdrawal symptoms identify "Type B" cocaine-dependent patients. Am J Addict 2008; 17: 60-4
45. Kampman K, Alterman AI, Volpicelli JR, et al. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychol Addict Behav 2001; 15: 52-9
46. Kampman K, Pettinati H, Volpicelli JR, et al. Cocaine dependence severity predicts outcome in outpatient detoxification from cocaine and alcohol. Am J Addict 2004; 13: 74-82
47. Koob GF. Dynamics of neuronal circuits in addiction: reward, antireward, and emotional memory. Pharmacopsychiatry 2009; 42: S32-41
48. Skolnick P, Volkow ND. Addiction therapeutics: obstacles and opportunities. Biol Psychiatry 2012; 72: 890-1
49. Mroziewicz M, Tyndale RF. Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. Addict Sci Clin Pract 2010; 5: 17-29
50. Ciraulo DA, Piechniczek-Buczek J, Iscan EN. Outcome predictors in substance use disorders. Psychiatr Clin North Am 2003; 26: 381-409
51. Mariani JJ, Pavlicova M, Bisaga A, et al. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry 2012; 72: 950-6
52. Carboni E, Spielewoy C, Vacca D, et al. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J Neurosci 2001; 21: 141-4
53. Mead AN, Rocha BA, Donovan DM, et al. Intravenous cocaine inducedactivity and behavioural sensitization in norepinephrine-, but not dopaminetransporter knockout mice. Eur J Neurosci 2002; 16: 514-20
54. Drouin C, Darracq L, Trovero F, et al. Alpha-1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci 2002; 22: 2873-84
55. Belzung C, Scearce-Levie K, Barreau S, et al. Absence of cocaine-induced place conditioning in serotonin 1B receptor knock-out mic. Pharmacol Biochem Behav 2000; 66: 221-5
56. Paladini CA, Williams JT. Noradrenergic inhibition of midbrain dopamine neurons. J Neurosci 2004; 24: 4568-75
57. Blanc G, Trovero F, Vezina P, et al. Blockade of prefronto-cortical alpha 1-adrenergic receptors prevents locomotor hyperactivity induced by subcortical damphetamine injection. Eur J Neurosci 1994; 6: 293-8
58. Pozzi L, Invernizzi R, Cervo L, et al. Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. J Neurochem 1994; 63: 195-200
59. Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state and statedependent cognitive processes. Brain Res Brain Res Rev 2003; 42: 33-84
60. Parsons LH, Koob GF, Weiss F. Extracellular serotonin is decreased in the nucleus accumbens during withdrawal from cocaine self-administration. Behav Brain Res 1996; 73: 225-8
61. Parsons LH, Koob GF, Weiss F. Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J Pharmacol Exp Ther 1995; 274: 1182-91
62. Cunningham KA, Anastasio NC. Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. Neuropharmacology 2014; 76: 460-78
63. McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drugseeking behavior. J Neurosci 2003; 23: 3531-7
64. Schmidt HD, Schassburger RL, Guercio LA, et al. Stimulation of mGluR5 in the accumbens shell promotes cocaine seeking by activating PKC gamma. J Neurosci 2013; 33: 14160-9
65. Kalivas PW. Neurobiology of cocaine addiction: implications for new pharmacotherapy. Am J Addict 2007; 16: 71-8
66. Simpson DD, Joe GW, Fletcher BW, et al. A national evaluation of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 1999; 56: 507-14
67. Hornykiewicz O. The mechanisms of action of L-DOPA in Parkinson's disease. Life Sci 1974; 15: 1249-59
68. Nutt JG, Woodward WR, Anderson JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol 1985; 18: 537-43
69. Amato L, Minozzi S, Pani PP, et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database Syst Rev 2011; 12: CD003352
70. Mooney ME, Schmitz JM, Moeller FG, et al. Safety, tolerability and efficacy of levodopa-carbidopa for cocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend 2007; 88: 214-23
71. Schmitz JM, Lindsay JA, Stotts AL, et al. Contingency management and levodopacarbidopa for cocaine treatment: a comparison of behavioral targets. Exp Clin Psychopharmacol 2010; 18: 238-44
72. Liu S, Green CE, Lane SD, et al. The influence of dopamine-B-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study. Pharmacogenet Genomics 2014; 24: 370-3
73. Kosten TR, George TP, Kosten TA. The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs 2002; 11: 491-9
74. Volkow ND, Ding YS, Fowler JS, et al. Cocaine addiction: hypothesis derived from imaging studies with PET. J Addict Dis 1996; 15: 55-71
75. Fleckenstein AE, Volz TJ, Riddle EL, et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007; 47: 681-98
76. Rush CR, Stoops WW, Hays LR. Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability, and efficacy. Drug Alcohol Depend 2009; 99: 261-71
77. Rush CR, Stoops WW, Sevak RJ, et al. Cocaine choice in humans during D-amphetamine maintenance. J Clin Psychopharmacol 2010; 30: 152-9
78. Greenwald MK, Lundahl L, Steinmiller CL. Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphinemaintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers. Neuropsychopharmacology 2010; 35: 2624-37
79. Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocainedependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 2001; 21: 522-6
80. Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004; 29: 969-81
81. Shearer J, Wodak A, van Beek I, et al. Pilot randomized double blind placebocontrolled study of dextroamphetamine for cocaine dependence. Addiction 2003; 98: 1137-41
82. Darracq L, Blanc G, Glowinski J, et al. Importance of the noradrenalinedopamine coupling in the locomotor activating effects of d-amphetamine. J Neurosci 1998; 18: 2729-39
83. Zhang XY, Kosten TA. Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. Biol Psychiatry 2005; 57: 1202-4
84. Zhang XY, Kosten TA. Previous exposure to cocaine enhances cocaine self-administration in an alpha-1 adrenergic receptor manner. Neuropsychopharmacology 2007; 32: 638-45
85. Shorter D, Lindsay JA, Kosten TR. The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: a pilot study. Drug Alcohol Depend 2013; 131: 66-70
86. Gaval-Cruz M, Weinshenker D. Mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Mol Interv 2009; 9: 175-87
87. Kitson TM. The disulfiram-ethanol reaction: a review. J Stud Alcohol 1977; 38: 96-113
88. Bourdelat-Parks BN, Anderson GM, Donaldson ZR, et al. Effects of dopamine-beta-hydroxylase genotype and disulfiraminhibition on catecholamine homeostasis in mice. Psychopharmacology (Berl) 2005; 183: 72-80
89. Carroll KM, Nich C, Ball SA, et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998; 93: 713-27
90. McCance-Katz EF, Kosten TR, Jatlow P. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend 1998; 52: 27-39
91. Petrakis IL, Carroll KM, Nich C, et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000; 95: 219-28
92. Oliveto A, Poling J, Mancino MJ, et al. Randomized, double-blind, placebocontrolled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend 2011; 113: 184-91
93. Schottenfeld RS, Chawarski MC, Cubells JF, et al. Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug Alcohol Depend 2014; 136: 36-42
94. Carroll KM, Nich C, Shi JM, et al. Efficacy of disulfiram and twelve step facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug Alcohol Depend 2012; 126: 224-31
95. Kosten TR, Wu G, Huang W, et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biol Psychiatry 2013; 73: 219-24
96. Spellicy CJ, Kosten TR, Hamon SC, et al. ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. PharmacogenetGenom. 2013; 23: 333-40
97. Shorter D, Nielsen DA, Huang W, et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and alpha1aadrenoceptor gene variation. Eur Neuropsychopharmacol 2013; 23: 1401-7
98. Weinshenker D. Cocaine sobers up. Nat Med 2010; 16: 969-70
99. Schroeder JP, Epps SA, Grice TW, et al. The selective dopamine beta-hydroxylase inhibitor nepicastat attenuates multiple aspects of cocaine-seeking behavior. Neuropsychopharmacology 2013; 38: 1032-8
100. Cooper DA, Kimmel HL, Manvich DF, et al. Effects of pharmacologic dopamine beta-hydroxylase inhibition on cocaineinduced reinstatement and dopamine neurochemistry in squirrel monkeys. J Pharmacol ExpTher 2014; 350: 144-52
101. Cunningham KA, Carbone CL, Anastasio NC, et al. Dopamine betahydroxylase inhibitor SYN117 decreases subjective effects of cocaine. College on Problems of Drug Dependence Annual Meeting Abstract #135; 2010. Available from: http://www.cpdd. vcu.edu/Pages/Meetings/Meetings-PDFs/2010Programbook.pdf
102. Available from: http://clinicaltrials.gov/ct2/show/NCT01704196? term=nepicastat&rank=2
103. Reis AD, Castro LA, Faria R, et al. Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr 2008; 30: 132-5
104. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004; 75: 233-40
105. Johnson BA, Ait-Daoud N, Wang XQ, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry 2013; 70: 1338-46
106. Kampman KM, Pettinati HM, Lynch KG, et al. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 2013; 133: 94-9
107. Umbricht A, DeFulio A, Winstanley EL, et al. Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug Alcohol Depend 2014; 140: 92-100
108. Kalivas PW. Neurobiology of cocaine addiction: implications for new pharmacotherapy. Am J Addict 2007; 16: 71-8
109. Peng XQ, Li X, Gilbert JG, et al. Gamma-vinyl GABA inhibits cocainetriggered reinstatement of drug-seeking behavior in rats by a non-dopaminergic mechanism. Drug Alcohol Depend 2008; 97: 216-25
110. Schiffer WK, Marsteller D, Dewey SL. Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaineinduced increases in nucleus accumbens dopamine. Psychopharmacology (Berl) 2003; 168: 339-43
111. Brodie JD, Figueroa E, Dewey SL. Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 2003; 50: 261-5
112. Brodie JD, Case BG, Figueroa E, et al. Randomized, double-blind, placebocontrolled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. Am J Psychiatry 2009; 166: 1269-77
113. Somoza EC, Winship D, Gorodetzky CW, et al. A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. JAMA Psychiatry 2013; 70: 630-7
114. Berezina TL, Khouri AS, Winship MD, et al. Visual field and ocular safety during short-term vigabatrin treatment in cocaine abusers. Am J Ophthalmol 2012; 154: 326-32
115. Pan Y, Gerasimov MR, Kvist T, et al. CPP-115, a potent gamma-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction. J Med Chem 2012; 55: 357-66
116. Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 2006; 67: 554-66
117. Ferraro L, Antonelli T, O'Connor WT, et al. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett 1988; 253: 135-8
118. Ferraro L, Antonelli T, Tanganelli S, et al. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 1999; 20: 346-56
119. Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009; 10: 561-72
120. Dackis CA, Lynch KG, Yu E, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003; 70: 29-37
121. Anderson AL, Reid MS, Li SH, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009; 104: 133-9
122. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005; 30: 205-11
123. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat 2012; 43: 303-12
124. Schmitz JM, Rathnayaka N, Green CE, et al. Combination of modafinil and damphetamine for the treatment of cocaine dependence: a preliminary investigation. Front Psychiatry 2012; 3: 77
125. Schmitz JM, Green CE, Stotts AL, et al. A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone. Drug Alcohol Depend 2014; 136: 100-7
126. Tonstad S, Heggen E, Giljam H, et al. Niccine, a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tob Res 2013; 15: 1492-501
127. Hoogsteder PH, Kotz D, van Spiegel PI, et al. The efficacy and safety of a nicotine conjugate vaccine (NicVAX) or placebo co-administered with varenicline (Champix) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial. BMC Public Health 2012; 12: 1052
128. Fahim RE, Kessler PD, Kalnik MW. Therapeutic vaccines against tobacco addiction. Expert Rev Vaccines 2013; 12: 333-42
129. Shen XY, Kosten TA, Lopez AY, et al. A vaccine against methamphetamine attenuates its behavioral effects in mice. Drug Alcohol Depend 2013; 129: 41-8
130. Kosten TA, Shen XY, O'Malley PW, et al. A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats. Prog Neuropsychopharmacol Biol Psychiatry 2013; 45: 223-9
131. Fox BS, Kantak KM, Edwards MA, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996; 2: 1129-32
132. Orson FM, Kinsey BM, Singh RA, et al. Vaccines for cocaine abuse. Hum Vaccin 2009; 5: 194-9
133. Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002; 20: 1196-204
134. Martell BA, Mitchell E, Poling J, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005; 58: 158-64
135. Martell BA, Orson FM, Poling J, et al. Cocaine vaccine for the treatment of cocaine dependence in methadonemaintained patients: a randomized, double=blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 2009; 66: 1116-23
136. Kosten TR, Domingo CB, Shorter D, et al. Vaccine for cocaine dependence: a randomized double-blind placebocontrolled efficacy trial. Drug Alcohol Depend 2014; 140: 42-7
137. Stoops WW, Glaser PE, Fillmore MT, et al. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J Psychopharmacol 2004; 18: 534-43
138. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000; 14: 53-60
139. Vosburg SK, Hart CL, Haney M, et al. Modafinil does not serve as a reinforcer in cocaine abusers. Drug Alcohol Depend 2010; 106: 233-6